AstraZeneca has temporarily halted two clinical trials combining experimental drugs to treat lung cancer, following reports of lung disease in some patients, the company said on Friday. The trials involve giving its drug AZD9291, which is currently awaiting regulatory approval, alongside the immune system-boosting medicine durvalumab, also known as MEDI4736, to treat patients with advanced […]

The U.S. Food and Drug Administration on Friday approved Merck & Co Inc’s immunotherapy, Keytruda, for patients with the most common form of lung cancer whose tumors produce a specific biological marker. The FDA approval for Keytruda in advanced non-small cell lung cancer is for patients whose tumors express PD-L1, a protein targeted by the […]

Novartis AG’s (NVS -1.46 %) new heart-failure treatment should cost about 17% less than what the company is charging in the U.S. because wide use of the drug would strain health-care budgets, a nonprofit research group said Friday. Entresto’s U.S. list price, also known as its wholesale acquisition cost, is $12.50 a day, or about […]

GlaxoSmithKline’s inhaled medicine Breo failed to prolong life in patients with chronic respiratory disease in a high-stakes clinical trial of 16,500 people, torpedoing hopes of a sales boost for the drug. Shares in Britain’s biggest drugmaker fell 1.5 percent on Wednesday, lagging a strong London market, in reaction to the news announced by the company […]

Novartis AG said on Friday it received European Union approval for Farydak, a treatment for multiple myeloma that the company said gives new options for adult patients whose disease has progressed following standard therapy. Novartis received similar approval for Farydak from the U.S. Food and Drug Administration in February for treating multiple myeloma, a form […]

U.S. regulators have approved a new dose of AstraZeneca’s blood thinner Brilinta for longer-term use in patients with a history of heart attacks, boosting prospects for a drug the company thinks will eventually sell $3.5 billion a year. The green light from the U.S. Food and Drug Administration (FDA), announced late on Thursday, could theoretically […]

AstraZeneca Plc on Thursday said the U.S. Food and Drug Administration approved a new dose of its blood thinner Brilinta intended for longer-term use in patients with a history of heart attack or a condition known as acute coronary syndrome. The FDA approved Brilinta tablets at a new 60 milligram dose that would be taken […]

A new drug in early development cuts cholesterol as much as two potent injections recently cleared for sale but lasts much longer, meaning it may need to be given only every three to six months, initial findings suggest. Results with Alnylam Pharmaceuticals and Medicines Co’s experimental product ALN-PCSsc highlight the competition for a market tipped […]

GlaxoSmithKline is banking on a major clinical trial to revive its flagging respiratory medicine business, with billions of dollars of sales riding on a positive result. Data from the so-called SUMMIT study, designed to show GSK’s Breo can prolong lives of patients with chronic lung disease, are expected as early as next month, nine years […]

The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being adequately controlled by existing drugs called statins. It might be a big step in the battle against heart disease – and […]